通过调节AXL介导的MAPK/NF-κB信号通路,C1632可以防止LPS引起的急性肺损伤

Yanan Mei1, Yihang Wu1, Yihui Zhai2

  • 1Respiratory Medicine Department, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.

概括

通过向AXL受体和MAPK/NF-κB通路,C1632有效地治疗急性肺损伤 (ALI) 和急性呼吸困扰综合征 (ARDS). 这种新型治疗剂可以减少肺炎和损伤,而不会产生显著的毒性.